Fig. 3: Follow-up small molecule screen validated aurora kinase inhibitors as effective in VP-MCC.

A Heatmap of select drug responses in follow-up screen that validated high-priority target subcategories. Please refer to Supplementary Fig. S5A for a heatmap of all 128 compounds included in the follow-up screen (n = 3). B Radar plot demonstrates a smaller mean AUC for AURK inhibitors in VP-MCC than VN-MCC cell lines. C Representative dose-response curves and IC₅₀ values of AZD2811 in MCC cell lines. Please refer to Supplementary Fig. S6A, B for dose-response curves and IC₅₀ values of additional AURK inhibitors. D The IC₅₀ value of AZD2811 (μM) ranked across 246 cancer cell lines included in the Dependency Map (gray) and MCC cell lines from our high-throughput screen (purple). AZD2811 was more potent in MKL-2, MKL-1, and WAGA (VP-MCC cell lines) than > 99% of other cancer cell lines included in this database. n = number of experimental replicates.